skip to main content
News and Events
  • Deep-sea bacteria inspire researchers to develop new ways to see, treat tumours

    by Peter Mothe | Sep 10, 2018

    The green sulphur bacteria has the most efficient known light-to-energy conversion ratio in the natural world, which is exactly why Dr. Zheng's team decided to copy its molecular structure to see if it could be used as a contrast agent.

    A hundred metres below the surface of the Black Sea, life is tough. At that depth, oxygen levels are low and sunlight is practically invisible to the human eye. But despite these adverse conditions, one organism still manages to thrive in this hostile environment. Its secret? An incredible ability to convert small amounts of light into energy.

    Scientists are fascinated by the way green sulphur bacteria use hyper-sensitive, antenna-like structures called chlorosomes to efficiently convert the tiny particles of light that reach this part of the sea into chemical energy. And recently a group of Toronto-based researchers has found a way to harness the power of these light-harvesting organelles for an unexpected purpose: to improve our ability to see and treat cancerous tumours hidden deep inside our bodies.  

    In a study published in Angewandte Chemie (June 2018; first author Dr. Kara Harmatys), a TFRI-funded New Frontiers Program Project Grant team led by Dr. Gang Zheng (Princess Margaret Cancer Centre) explains how they set out to replicate the unique properties of these incredibly efficient light-harvesting organisms in their lab, hoping that they could serve as a contrast agent that would allow doctors to better understand the shape and size of hard-to-reach tumours.

    After successfully creating a biomimetic system that copied the molecular structure of the chlorosome organelles that live in the bacteria, the team was faced with a second challenge: making it safe and useful in humans. To do this, they drew inspiration from a high-density lipoprotein nanoparticle that transports fat molecules in human blood, which they managed to replicate in their lab and combine with their newly created biomimetic chlorosome.

    This dual-biomimetic system is the first of its kind and has several promising applications: in addition to being a contrast agent that will help researchers see tumours more clearly, it will also play a role in photodynamic therapy (PDT), a promising treatment against cancer that uses light-activated drugs, called photosensitizing agents, to kill cancer cells.

    “We envision this agent will improve current surgical procedures by helping surgeons view tumours they are operating on in real-time, while also providing minimally invasive and curable PDT for surgically inaccessible tumours or tumours that are close to anatomical structures,” said Dr. Zheng. “So far we’ve had promising preliminary results and are excited to continue exploring the imaging and phototherapeutic applications of this agent.”


    Multipronged Biomimetic Approach to Create Optically Tunable Nanoparticles


    Kara M. Harmatys, Juan Chen, Danielle M. Charron, Christina M. MacLaughlin, and Gang Zheng


    This study is partly funded by a Terry Fox New Frontiers Program Project Grant in Nanoparticle-Enhanced Photoacoustic Imaging for Cancer Localization and Therapeutic Guidance

  • Scientists use protein found in mosquito virus to suppress RNAi pathway, opening door to make oncolytic viruses more effective

    by Peter Mothe | Sep 10, 2018


    A group of TFRI-funded investigators based in Ottawa has discovered that suppressing the RNA interference pathway (RNAi), an antiviral response system once believed to be unique to invertebrates, fungi and plants, could make oncolytic viruses (OVs) more effective. This discovery was possible thanks to the development of a novel OV that incorporates a protein found in a virus first isolated in mosquitoes in Japan 70 years ago.

    The team led by Drs. Carolina Ilkow and John Bell (Ottawa Hospital Research Institute/University of Ottawa) hypothesized that RNAi could play a roll in antiviral responses in human cancer cells: “Considering the discovery of mammalian antiviral RNAi in embryonic stem cells and the genetic similarities between cancer cells and embryonic stem cells, we hypothesized a role for antiviral RNAi in cancer cells,” they explain in their paper published in the Journal for ImmunoTherapy (June 2018).

    To test for the presence of RNAi in cancer cells, the researchers engineered a virus that modified the features of a known OV – VSVΔ51 – to incorporate a protein known as B2, a viral suppresser of the RNAi pathway present in an insect virus known as the Nodamura virus. This enabled them to characterize the novel OV and to demonstrate the interplay between the B2-expressing virus and RNA processing pathways in cancer.

    When they applied this novel OV to 38 different human cancer cell lines in the lab, they were amazed at the results: not only was the new OV much better at targeting and killing cancer cells, it also had the ability to rapidly proliferate within the cancer cell environment without attacking other cells. These results allowed them to conclude that suppressing RNAi may improve OV replication and could enhance cancer cell susceptibility to OVs, opening the door to the development of viruses that can target and kill human cancer cells more efficiently.


    Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference


    Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell and Carolina S. Ilkow.


    This study is partially funded by a Terry Fox New Frontiers Program Project Grant: Canadian Oncolytic Virus Consortium (COVCo)

  • Upcoming Node Events and Cancellation of 2019 ASM

    by Peter Mothe | Sep 10, 2018

    We encourage members of our research community to Save the Date to participate/attend the planned regional node research events featuring talks and presentations by our funded investigators during the coming year.

    Please note that TFRI will NOT hold its Annual Scientific Meeting in 2019.

    Upcoming node research days: 

  • TFRI launches 2018 Terry Fox Run Challenge

    by Peter Mothe | Aug 03, 2018
    In 2017, members from the COVCo research group raised over $14,000 for the Terry Fox Run, and won TFRI's Terry Fox Run Challenge.


    EVERY YEAR, the Terry Fox Research Institute (TFRI) organizes the Terry Fox Run Challenge, a friendly contest in which our research teams compete against each other to see which can raise more funds for the Terry Fox Foundation. 

    In 2017, almost all of our research teams participated in the challenge, raising over $55,000 for cancer research. The top honour went to the Ottawa-based Canadian Oncolytic Virus Consortium (COVCo) team, which raised an inspiring $14,028.

    Following this tradition, the TFRI is proud to launch the 2018 Terry Fox Run Challenge. Our goal for this year is to surpass the amount of money raised in 2017.

    The year's Terry Fox Run will be held on Sunday, Sept. 16 in locations across the country. Researchers will be easily identifiable thanks to their flashy purple t-shirts.

    Researchers wanting to register their own teams can do so at http://www.terryfox.org/run/teams/. We'd also like to invite anyone to join or donate to the TFRI Headquarters team captained by Dr. Victor Ling, and welcome anyone who has already joined us to our growing team.

    2017 Images

    20170917_095941_resizedA few members from the TFRI Headquarters team pose for a picture during the 2017 Terry Fox Run at Stanley Park in Vancouver.

    20170917_095941_resizedMembers from various research projects pose for a group shot at Stanley Park. 



    Members of from the Hippo Team led by Dr. Jeff Wrana pose for a shot at a Terry Fox Run in Toronto. 


    Members from Dr. Gang Zheng's lab -- The Gang-sters -- at a Terry Fox Run in Toronto.

    Members from Dr. Aly Karsan's team, The Bloodrunners, pose for a picture at Stanley Park. 

    20170917_100513_resized_1  20170917_100513_resized_1

    TFRI Headquarters team members enjoying their run at Stanley Park.

    Terry Fox Challenge 2017: Participating Teams

    Last year's participants included:

    • TFRI Headquarters 
    • Lung Team
    • TFRI - Reiman Team
    • COVCo
    • TFRI - Hypoxia
    • The Bloodrunners
    • iTNT
    • TFRI - Team Hippo
    • The Gang-sters
    • TFRI - Stemness
    • TFRI - Vancouver Prostate Centre
    • GCRC Foxtrotters
    • Guelph Cancer Biotherapy Research Group
    • TFRI HQ Genome Sciences
    • TFRI - GBM Team
    • TFRI - PPG
  • Pilot project network teams report steady progress in first year of working together

    by Peter Mothe | Aug 02, 2018

    Leaders from the Terry Fox Research Institute, BC Cancer and the Princess Margaret Cancer Centre pose during the launch of the TF4CN in February 2017. 

    FOSTERING UNPRECEDENTED COLLABORATIONS, harmonizing complex research methods and creating the basic framework for a digital platform that allows patient data to be shared, stored and analyzed. These are just three of the many achievements that some of the nation’s top cancer researchers are crediting to an ambitious cancer centre network led by The Terry Fox Research Institute.

    The Terry Fox Canadian Comprehensive Cancer Centres Network (TF4CN), a two-year pilot project that brings together investigators from Vancouver’s BC Cancer and Toronto’s Princess Margaret Cancer Centre, has reached these milestones in just over a year—making researchers hopeful about the potential benefit the network could have on patients across the nation.

    “Over the past year we’ve been working closely with Dr. Pamela Ohashi’s lab in Toronto and have been able to harmonize how we manufacture T-cells for use in immunotherapy,” says Dr. Brad Nelson (BC Cancer), a world-famous cancer researcher who co-leads one of the four projects being piloted as part of the TF4CN. “While this may not seem like a very big deal it actually opens doors for fascinating new collaborations between the two teams that could have a real impact on patients.”

    According to Dr. Nelson, using similar methods to create T-cells will allow investigators in both centres to share samples for use in research and make it possible for them to collaborate on clinical trials that reach a higher number of patients—something that was infeasible in the past.

    “Our vision is that we will be able to do immunotherapy trials in the future at different centres throughout the TF4CN network and generate data that is comparing apples to apples from centre to centre,” says Dr. Nelson. “If we pull this off, Canada would be one of the only places in the world that is organized this way for immunotherapy research.”


    Helping to make precision medicine a reality

    When the TF4CN was launched in April of 2017, authorities from the three participating institutions were aware of the challenges that would need to be overcome for true inter-institutional collaboration to occur. They would need to step out of silos, try to reduce the red tape associated with project implementation and identify new ways to work within and across the boundaries of institutional practices and policies.

    While they knew this would take some time, they were motivated by the project’s end goal of making the promise of precision medicine a reality.

    “Bringing researchers and institutions together is always tough, but what we’ve seen so far is that TF4CN has been extremely successful in creating a space for researchers and administrators to collaborate and decide how they are going to collect and share information with each other in the future, which is helping to accelerate the implementation of precision medicine in Canada,” says Dr. Victor Ling, TFRI’s president and scientific director.

    For him, breaking down institutional silos and creating true collaboration between researchers is necessary if this promising framework for care, which is based on providing the right treatment at the right time for the right patient, is to become a reality.

    “Precision medicine could allow doctors to tailor treatments to suit their patient’s unique needs, but making it a reality depends on our ability to create, share and analyze large amounts of data collected from patients across the country,” says Dr. Ling. “Unless we come together to decide how we’re all going to collect this data in the same way and figure out how we can share this data between each other, this promise will never materialize.”  

    Piloting the medicine of the future

    During the first phase of the project, the TF4CN is helping to make this happen by bringing researchers together to work on four distinct projects, including the genomic profiling of patients with metastatic colorectal cancer, the improvement of immunotherapy for patients with high-grade serous ovarian cancer, the use of quantitative molecular imaging to improve the management of prostate cancer, and the creation of an IT and data governance platform that will make data sharing and analysis possible.  

    This last project is perhaps the most pivotal part of the network, as getting it right could be the basis on which a national infrastructure to store, link, share, and learn from data in digital form could be built.

    After a year of hard work, this infrastructure is steadily coming to life, with experts in Toronto and Vancouver coming together to create joint policies for data sharing, as well as developing a beta version of an IT platform that can be used to share clinical, genomic, imaging and pathology data between the two centres.

    As it moves into its second year, network leaders hope to test this platform by sharing data collected in the three other projects that make up this pilot phase. They also hope to slowly start expanding the network by linking up with research facilities in Montreal, which recently came together under another TFRI-led pilot project known as the Montreal Cancer Consortium.

    For Dr. Ling, these inter-institutional collaborations are at the forefront of collaborative science and provide a model on which a pan-Canadian network of cancer centres could be built.   

    “The Terry Fox Canadian Comprehensive Cancer Centre Network is providing much-needed evidence on how best to do this by modelling a broader vision for data sharing and collaborative translational and clinical research that will hopefully accelerate the implementation of precision medicine in Canada,” he says.

    TF4CN Partner Institutions


  • Leukemia researchers discover genetic screening tool to predict healthy people at risk of developing aggressive form of leukemia

    by Peter Mothe | Jul 11, 2018

    Drs. John Dick and Sagi Abelson discuss the findings of their research published in Nature. (Video: UHN)

    An international team of leukemia scientists that includes TFRI-funded researchers has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer.  

    The findings, published in Nature (July 9, 2018), illuminate the 'black box of leukemia' and answer the question of where, when and how the disease begins, says co-principal investigator Dr. John Dick (Princess Margaret Cancer Centre), who leads TFRI's Stemness Project

    "We have been able to identify people in the general population who have traces of mutations in their blood that represent the first steps in how normal blood cells begin on a pathway of becoming increasingly abnormal and puts them at risk of progressing to AML. We can find these traces up to 10 years before AML actually develops," says Dr. Dick. "This long time window gives us the first opportunity to think about how to prevent AML."

    Dr. Dick is also a Professor, Department of Molecular Genetics, University of Toronto, holds the Canada Research Chair in Stem Cell Biology, and is Co-Leader of the Acute Leukemia Translational Research Initiative at the Ontario Institute for Cancer Research.

    Study author Dr. Sagi Abelson, a post-doctoral fellow in the Dick lab, says: "AML is a devastating disease diagnosed too late, with a 90 per cent mortality rate after the age of 65. Our findings show it is possible to identify individuals in the general population who are at high risk of developing AML through a genetic test on a blood sample.

    "The ultimate goal is to identify these individuals and study how we can target the mutated blood cells long before the disease actually begins."

    The study builds on Dr. Dick's 2014 discovery that a pre-leukemic stem cell could be found lurking amongst all the leukemia cells that are present in the blood sample taken when a person is first diagnosed with AML. The pre-leukemic stem cell still functions normally but it has taken the first step in generating pathway of cells that became more and more abnormal resulting in AML (Nature, February 12, 2014), and continues his quest to trace every step in the evolution of AML, starting with blood cells from healthy people.

    "Our 2014 study predicted that people with early mutations in their blood stem cells, long before the disease appears and makes them sick, should be able to be detected within the general population by testing a blood sample for the presence of the mutation." says Dr. Dick.

    Co-principal investigator Dr. Liran Shlush, a former fellow in the Dick lab, and now Senior Scientist at the Weizmann Institute in Israel, led the approach to use data from a large European population health and lifestyle study that tracked 550,000 people over 20 years to determine correlations to cancer.

    The leukemia team extracted the data from more than 100 participants who developed AML six to 10 years after joining the study, plus the data from an age-matched cohort of more than 400 who did not develop the disease.

    Dr. Dick says: "We wanted to know if there was any difference between these two groups in the genetics of their 'normal' blood samples taken at enrollment. To find out, we developed a gene sequencing tool that captured the most common genes that get altered in AML and sequenced all the 500 blood samples."

    The answer was "Yes". The seeds of the blood system started picking up mutations years before an individual was diagnosed with AML, a finding that enabled the team to predict accurately who had been at risk of disease progression.

    Furthermore, the team used advanced computational technology to assay the information obtained from routinely collected blood tests taken over 15 years in Israel and housed in a massive database of 3.4 million electronic health records.

    The study has deepened our understanding of the distinction between AML and a common feature of aging called ARCH–age-related clonal hematopoiesis–whereby blood stem cells acquire mutations and become a little more proliferative. For the vast majority of people this is just a completely benign feature of aging.  

    "Every AML patient has ARCH but not everyone with ARCH gets AML," explains Dr. Dick.

    The study, Prediction of acute myeloid leukaemia risk in healthy individual, is available from Nature, here: https://go.nature.com/2zpsdLz


  • L’Institut de recherche Terry Fox et leurs partenaires de recherche de Montréal forment un consortium en vue d’offrir des traitements plus personnalisés aux personnes atteintes de cancer au Québec

    by Peter Mothe | Jun 28, 2018


      • Dr Victor Ling, président et directeur scientifique de l’IRTF : Bio
      • Dr Anne-Marie Mes-Masson, responsable du pôle Québec de l’IRTF: Bio 
      • Dr John Stagg, co-chercheur principal (CRCHUM)Bio Photo
      • Dr Ian Watson, co-chercheur principal (CRCG): Bio Photo
      • Mr Stan Czebruk. Stage IV melanoma patient (MUHC)Photo
      • Mr Yves Tellier, Stage IV melanoma patient (CRCHUM)Photo
    • VIDÉO
      • Images non montées du Dr John Stagg (CRCHUM) : Télécharger

    Jeudi 28 juin 2018
    (Click here for English version)

    MONTRÉAL - Dans le but d’améliorer les traitements offerts aux 18 000 patients atteints de cancer traités annuellement, les meilleurs chercheurs, centres de cancérologie et hôpitaux de Montréal et l’Institut de recherche Terry Fox ont formé un partenariat afin de réaliser de nouvelles avancées dans le domaine de la médecine personnalisée et de précision.

    Le Consortium contre le cancer de Montréal (CCM) regroupe plusieurs institutions, soit le Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), le Centre de recherche sur le cancer Goodman (CRCG), le Centre de recherche de l’Hôpital Maisonneuve-Rosemont, l’Institut de recherche en immunologie et en cancérologie (IRIC), l’Hôpital général juif (HGJ), le Centre d’innovation Génome Québec, l’Université McGill, l’Université de Montréal et l’Institut de recherche du Centre universitaire de santé McGill (IR-CUSM).

    Pour l’Institut de recherche Terry Fox, le lancement de ce consortium marque une nouvelle étape vers l’atteinte de son objectif d’accélérer l’application de la médecine de précision pour tous les Canadiens. Le Consortium est le second projet pilote créé par l’Institut dans le cadre de sa stratégie visant à former un réseau pancanadien de centres de cancérologie.

    Les membres du projet pilote montréalais poursuivront l’élaboration d’une nouvelle stratégie de traitement du cancer qui renforce le système immunitaire du patient pour qu’il combatte le cancer. Ce traitement appelé immunothérapie a récemment donné des résultats impressionnants chez certains patients.

    Yves Tellier, 70 ans, a remarqué une petite tache foncée sur sa jambe. Ce qu’il croyait être une blessure causée par un bâton de golf s’est avéré être un mélanome au stade IV. C’était il y a six ans et, lorsqu’une tumeur métastatique a été découverte sur sa colonne vertébrale en 2013, il a reçu des traitements d’immunothérapie et de chimiothérapie au Centre hospitalier de l’Université de Montréal. Son état de santé s’est amélioré de façon spectaculaire. « Je suis actuellement en rémission complète et j’ai très peu d’effets secondaires. Je mène maintenant une vie active normale. Je peux faire du ski, du vélo, de la plongée libre et jouer au golf. N’eût été ce traitement, je suis convaincu que je ne serais pas vivant aujourd’hui. Grâce à ce nouveau consortium, les chercheurs ne travailleront plus chacun de leur côté. Le regroupement aidera à faire progresser les traitements contre le cancer, et c’est une excellente nouvelle pour les patients. »

    L’immunothérapie a aussi changé la vie de Stan Czebruk. « C’était en 2009. Je faisais une randonnée en Écosse quand mon épouse m’a appelé pour m’annoncer que j’avais le cancer. C’était un mélanome sur mon oreille gauche qui s’est ensuite propagé aux poumons et au cerveau », explique ce Montréalais âgé de 60 ans qui est traité au Centre universitaire de santé McGill. Lui aussi est en rémission et il subira son dernier traitement d’immunothérapie au début du mois d’août. « Le parcours a été long, mais j’ai une grande confiance dans le système de santé. J’ai grand espoir que davantage de recherches seront faites et que d’autres traitements seront trouvés. »

    Stan Czebruk et Yves Tellier

    Le Consortium contre le cancer de Montréal se concentrera en premier lieu sur les traitements d’immunothérapie pour le mélanome et la leucémie aiguë. Il se servira par la suite des connaissances et des ressources acquises pour soutenir les traitements d’autres types de cancers. « À Montréal, nous avons le leadership dans ce domaine de recherche. Il y a également un besoin clinique à combler en matière de nouveaux traitements à élaborer afin que davantage de patients traités au moyen de cette thérapie obtiennent de meilleurs résultats. Actuellement, seulement 20 à 30 % des patients qui reçoivent des traitements d’immunothérapie répondent bien à ceux-ci », indique le co-chercheur principal du projet pilote, le Dr John Stagg, chercheur et professeur agrégé du CRCHUM et de la Faculté de pharmacie de l’Université de Montréal.

    Les chercheurs du CCM, en travaillant en collaboration, tenteront également de mieux comprendre comment les divers aspects du système immunitaire sont liés à la leucémie aiguë et pourquoi la thérapie fonctionne chez certains patients, mais pas chez d’autres. Ils espèrent découvrir de nouveaux biomarqueurs et de nouvelles cibles qui répondront aux traitements d’immunothérapie.

    « Au total, le Consortium contre le cancer de Montréal tirera profit des données de plus de 18 000 patients annuellement et de plus de 50 essais cliniques continus en immunothérapie et en médecine de précision dans le but de créer l’un des pôles d’innovation en oncologie les plus centrés sur le patient au Canada », déclare le Dr Ian Watson, Chaire de recherche du Canada en génomique fonctionnelle du mélanome et professeur adjoint, Département de biochimie de l’Université McGill, membre du Centre de recherche sur le cancer Goodman et co-chercheur principal du projet de CCM.

    Dr Ian Watson (GCRC) et Dr John Stagg (CRCHUN). 

    Plusieurs organisations appuyant l’initiative verseront une somme totale de 6,5 M$ au CCM au cours des deux prochaines années. À titre de catalyseur du projet, l’IRTF fournira 2 M$. Parmi les autres bailleurs de fonds, il y a notamment Oncopole, Génome Québec, le Centre de recherche sur le cancer Goodman et l’Institut du cancer de Montréal.

    « Nous sommes ravis de voir la formation de ce partenariat avec les meilleurs chercheurs, cliniciens et centres de cancérologie universitaires et de santé de Montréal. En regroupant leurs travaux et en établissant ces nouvelles collaborations, nous créons un nouveau modèle de travail qui a le potentiel de changer réellement les choses dans les cliniques. Ce sont d’excellentes nouvelles pour les patients vivant ici, au Québec, et partout au Canada », affirme le Dr Victor Ling, président et directeur scientifique de l’IRTF.

    « Ce partenariat est le résultat d’une importante mobilisation entre les différents hôpitaux et centres de recherche de Montréal impliqués dans la lutte contre le cancer. Nous sommes très heureux d’offrir une contribution de 750 000 $ pour créer ce consortium qui répond au besoin de structurer l’écosystème en vue d’offrir des solutions innovantes aux patients », mentionne Stéphanie Lord-Fontaine, directrice générale d’Oncopole.

    « Génome Québec salue cette initiative de l’Institut de recherche Terry Fox qui a pour objectif de réunir les forces et les expertises de la recherche en cancer ainsi que des institutions de santé de Montréal. Nous sommes fiers de participer, à titre de partenaires, au soutien des études génomiques des projets concernés. Le Consortium contre le cancer de Montréal (CCM) favorisera l’intégration des données génomiques en clinique et l’implantation de la médecine de précision. Nous sommes persuadés que le CCM contribuera à faire de Montréal un environnement compétitif, optimal et durable pour la recherche sur le cancer, et ce, pour le plus grand bénéfice des patients », souligne Daniel Coderre, président-directeur général de Génome Québec.

    Partenaires de recherche


    À propos de l’Institut de recherche Terry Fox (IRTF) 

    Lancé en octobre 2007, l’Institut de recherche Terry Fox est une idée de la Fondation Terry Fox et fonctionne aujourd’hui comme son organisme de recherche. L’IRTF cherche à améliorer de manière déterminante les résultats de la recherche sur le cancer pour les patients, grâce à une approche très collaborative, axée sur les équipes, avec des étapes clés de recherche qui permettront de transformer rapidement les découvertes en solutions concrètes pour les patients atteints de cancer dans le monde entier. L’IRTF collabore avec plus de 80 centres de cancérologie et organismes de recherche d’un bout à l’autre du Canada. Le siège social de l’IRTF est à Vancouver, Colombie-Britannique. Pour obtenir plus d’information, prière de nous visiter au www.tfri.ca et de nous suivre sur Twitter (@tfri_research).

    À propos du Centre de recherche du CHUM (CRCHUM

    Le Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM) est l'un des plus importants centres de recherche en milieu hospitalier en Amérique du Nord. Sa mission est d'améliorer la santé chez l'adulte grâce à un continuum de recherche allant des sciences fondamentales à la santé des populations, en passant par la recherche clinique. Plus de 1819 personnes travaillent au CRCHUM dont 465 chercheurs et 641 étudiants et stagiaires de recherche. chumontreal.qc.ca/crchum

    À propos du Centre de recherche sur le cancer Goodman (GCRC)

    Situé dans le Complexe des sciences de la vie de l’Université McGill, le Centre de recherche sur le cancer Rosalind et Morris Goodman (CRCG) est un pôle de recherche de pointe sur le cancer qui attire et conserve dans ses rangs de brillants chercheurs des quatre coins du monde. Établi en 1978, le CRCG (à l’époque le Centre du cancer McGill) réalise des percées scientifiques qui nous permettent d’étudier le cancer aussi bien sur le plan du génome qu’aux niveaux cellulaire et moléculaire, afin de mieux comprendre ses mécanismes d’évolution, de propagation et de résistance aux traitements. Le Centre compte actuellement 27 équipes de recherche attitrées pourvues de plateformes technologiques de pointe, du personnel de recherche et de soutien, et plus de 200 stagiaires. Les activités menées au CRCG, première ligne d’attaque contre le cancer, sont axées sur la recherche fondamentale et visent à comprendre pourquoi certains cancers résistent aux traitements dans le but de trouver de nouvelles cibles et de nouveaux traitements.

    Contacts Mèdias

    Pour de plus amples informations ou pour obtenir une entrevue, veuillez communiquer avec:
    Jason Clement, McGill University, 
    514-865-6990 (cell); 

    Julie Cordeau-Gazaille, Université de Montréal,

    Kelly Curwin, TFRI,
    cell: 778-237-8158;

    Julie Robert, MUHC
    (pour une entrevue avec M. Stan Czebruk)

    Jacinthe Ouellette, CHUM/CRCHUM
    (pour une entrevue avec M. Yves Tellier)
    514-246-0567 (cell.);

  • The Terry Fox Research Institute and Montreal research partners form consortium to provide more personalized treatments for cancer patients in Québec

    by Peter Mothe | Jun 28, 2018

    Representatives from partnering institutions participate in the unveiling of the Montreal Cancer Consortium Pilot Project. 


    • PHOTOGRAPHS AND BIOS (As Available)
      • Dr. Victor Ling, TFRI President and Scientific DirectorBio
      • Dr. Anne-Marie Mes-Masson, TFRI Node President (Quebec): Bio 
      • Dr. John Stagg, Co-Principal Investigator (CRCHUM): Bio Photo
      • Dr. Ian Watson, Co-Principal Investigator (GCRC)Bio | Photo
      • Mr. Stan Czebruk. Stage IV melanoma patient (MUHC)Photo
      • Mr. Yves Tellier, Stage IV melanoma patient (CRCHUM)Photo
    • VIDEO
      • B-Roll of Dr. John Stagg (CRCHUM): Download

    Thursday, June 28, 2018
    (Click here for French version)

    MONTRÉAL - Seeking to improve treatments for 18,000 annual cancer patients, leading researchers, cancer centres and hospitals in Montreal and The Terry Fox Research Institute have partnered to generate new advances in personalized and precision medicine.

    The multi-institutional Montreal Cancer Consortium (MCC) comprises the Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Goodman Cancer Research Centre (GCRC), Centre de Recherche Hôpital Maisonneuve-Rosemont, Institute for Research in Immunology and Cancer (IRIC), Jewish General Hospital (JGH), McGill University, the Université de Montréal, Génome Québec Innovation Centre, and the Research Institute of the McGill University Health Centre (RI-MUHC).

    For the Terry Fox Research Institute, the launch of this consortium marks another step forward in accelerating precision medicine for all Canadians. The consortium is the second pilot project the Institute has created as part of its strategy to form a pan-Canadian network of linked cancer centres from coast to coast.

    The Montreal pilot project members will further develop a new cancer treatment strategy that enhances an individual’s immune system to fight cancer called immunotherapy, which has recently shown impressive results for some patients.

    A small dark spot on his lower leg that Yves Tellier, 70, thought was an injury from a golf club turned out to be Stage IV melanoma. That was six years ago and when metastatic disease was found on his spine in 2013, he was treated with immunotherapy and chemotherapy at the Centre hospitalier de l'Université de Montréal.  His health improved dramatically. “I am currently in complete remission with very few side effects. I now have a normal, active life. I can ski, golf, cycle and scuba dive.  Had it not been for this treatment, I am convinced I would not be alive today.  Thanks to this new consortium, instead of working on their own, the amalgamation of these researchers will help advance cancer treatments, and that is great news for patients.

    Immunotherapy changed Stan Czebruk’s life. “It was in 2009. I was hiking in Scotland, when my wife called me and announced that I had cancer. It was a melanoma on my left ear that spread later to my lungs and brain,” explains the 60-year-old Montrealer, who is treated at the McGill University Health Centre. He, too, is now in remission and will undergo his last immunotherapy treatment at the beginning of August. “It has been a long journey, but I have a lot of faith in the health care system and great hope that more research will be done and more treatments will be found.

    Stage IV melanoma patients Stan Czebruk and Yves Tellier speak at the launch of Montreal Cancer Consortium.

    The Montreal Cancer Consortium will focus on immunotherapy treatments for melanoma and acute leukemia initially and use the knowledge and resources gained to support other cancer types. “We have both leadership in this research area in Montreal and also an unmet clinical need for new treatments to be developed so that more patients treated with this therapy have better outcomes. Currently only 20-30 per cent of patients who receive immunotherapy respond well to the treatment,” remarks pilot project co-principal investigator Dr. John Stagg, CRCHUM researcher and associate professor, Faculty of Pharmacy, Université de Montréal.

    Working together, the MCC researchers will also aim to better understand how various aspects of the immune system relate to acute leukemia and why therapy works for some patients but not others. They hope to identify new biomarkers and novel targets that will respond to immunotherapy treatments.

    “In total, the Montreal Cancer Consortium will harness the data power of more than 18,000 patients annually and more than 50 ongoing precision medicine and immunotherapy clinical trials, with the goal of developing one of the most patient-centric oncology innovation poles in Canada,” says Dr. Ian Watson, Canada Research Chair in Functional Genomics of Melanoma and assistant professor, Department of Biochemistry at McGil, member of the  Goodman Cancer Research Centre, and co-principal investigator for the MCC project.

    Drs. Ian Watson (GCRC) and John Stagg (CRCHUN) will be co-principal investigators for the new pilot project. 

    The MCC will receive $6.5 million over the next two years from several organizations supporting the initiative. As the project catalyst, TFRI is providing $2 million and Oncopole, Genome Québec, Goodman Cancer Research Centre and Institut du Cancer de Montréal are among several other co-funders.

    “We are delighted to see the formation of this partnership with Montreal’s leading health and academic cancer centres, researchers and clinicians. In consolidating their work, and forging these new collaborations, we are creating a new working paradigm that has the potential to make a real difference in the clinic and that is great news for patients living here in Quebec and anywhere in Canada,” says Dr. Victor Ling, TFRI’s president and scientific director.

    “This partnership is the outcome of an important mobilization effort across different Montreal hospitals and research centers involved in the fight against cancer. We are proud to contribute $750,000 to the consortium creation that responds to the co-ordination needed to bring innovative solutions to patients,” explains Stéphanie Lord-Fontaine, executive director of Oncopole.

    “Génome Québec salutes this initiative of the Terry Fox Research Institute that aims to bring together cancer research organizations and experts, and Montréal’s health institutions. We are proud to participate, as a partner, in supporting genome studies in the projects involved. The Montreal Cancer Consortium (MCC) promotes clinical integration of genomic data and the implementation of precision medicine. We are convinced that the MCC will help make Montréal a competitive, ideal and sustainable environment for cancer research, for the greater good of patients,” says Daniel Coderre, president and CEO of Génome Québec.

    Partner Institutions


    About The Terry Fox Research Institute (TFRI)

    Launched in October 2007, The Terry Fox Research Institute is the brainchild of The Terry Fox Foundation and today functions as its research arm. TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with more than 80 cancer hospitals and research organizations across Canada. TFRI headquarters are in Vancouver, B.C. For more information please visit www.tfri.ca and follow us on Twitter (@tfri_research).

    About Centre de recherche du Centre hospitalier de l'Université de Montréal (CHUM)

    The Centre de recherche du Centre hospitalier de l'Université de Montréal is one of North America’s leading hospital research centres. It strives to improve adult health through a research continuum covering such disciplines as the fundamental sciences, clinical research and public health. Over 1,819 people work at CRCHUM, including 465 scientists and 641 students and research assistants chumontreal.qc.ca/crchum

    About the Goodman Cancer Research Centre (GCRC)

    The Rosalind and Morris Goodman Cancer Research Centre (GCRC), located within McGill University’s Life Sciences Complex, is a state-of-the-art hub for ground-breaking cancer research that attracts and retains top scientists from around the world. Originally established in 1978 as the McGill Cancer Centre, the GCRC leads scientific advances that enable it to investigate cancer at a genomic, cellular and molecular level, and to understand how cancer progresses, spreads and resists therapies. The GCRC currently comprises 27 dedicated research teams with cutting-edge technology platforms, research and support staff and over 200 trainees. Research activities at the GCRC represent a first line of defense in the fight against cancer, with focus on fundamental research to understand why cancers fail to respond to treatment and translating findings into new targets and therapies.

    Media Contacts

    For more information, please contact:
    Jason Clement, McGill University,
    514-865-6990 (cell); 

    Julie Cordeau-Gazaille, Université de Montréal,

    Kelly Curwin, TFRI,
    cell: 778-237-8158;

    To interview Mr. Stan Czebruk, please contact:
    Julie Robert, MUHC

    To interview Mr. Yves Tellier, please contact:
    Jacinthe Ouellette, CHUM/ CRCHUM
    514-246-0567 (cell.);

  • "Celebrate failure!" says TFRI’s leader in new book celebrating Chinese Canadians

    by Peter Mothe | Jun 12, 2018

    A new book on on Chinese Canadian legacies published by Province of British Columbia Ministry of Tourism, Arts and Culture highlights Dr. Ling's work at the Terry Fox Research Institute. 

    remarks TFRI President and Scientific Director Dr. Victor Ling, who is among several prominent Chinese Canadians featured in a newly published 180-page, full-colour book titled Celebration: Chinese Canadian Legacies in British Columbia. “As a young person, I learned to imagine what success would be like and let that vision sustain me through the long dark periods of waiting and dealing with repeated failures.”

    Published by the Province of British Columbia Ministry of Tourism, Arts and Culture, the book evolved as part of a legacy following an apology by the British Columbia Legislature for the historical wrongs endured by Chinese Canadians. It highlights the contributions Chinese Canadians have made to this country and province – from serving in the military to playing an important part of its social, cultural and economic fabric. 

    Dr. Ling is described as iconic figure in the field of cancer research. He refers to his role at TFRI “as a matchmaker in bringing the best scientists from different institutions to work on collaborative research on more effective and larger-scale research studies.”  He attributes his successes to his father and those who mentored him in his scientific research.

  • Three top Canadian research teams receive $13 million to solve key cancer challenges

    by Peter Mothe | Jun 12, 2018

    From left to right: Drs. Greg Czarnota (Sunnybrook Health Sciences Centre), David Malkin (Hospital for Sick Children) and David Huntsman (BC Cancer, UBC).

    (Click here for French version)

    VANCOUVER - Three outstanding cancer research teams will receive nearly $13 million to continue their investigations into rare tumours, an inherited disorder (Li-Fraumeni Syndrome) and the use of magnetic resonance imaging (MRI) and ultrasound to improve treatments for breast cancer.

    Two teams primarily based in Ontario and the other in BC will receive the funding from the Terry Fox Research Institute (TFRI) as winners of its 2018 Terry Fox New Frontiers Program Project Grant (PPGs) competition.

    “These three teams have demonstrated that they are able to think outside the box and create really innovative projects that tackle some of the most challenging problems in cancer research. They bring together leading researchers with complementary skills to investigate different aspects of a given area of cancer research to find solutions that could yield positive results for patients in the short term,” says Dr. Victor Ling, TFRI president and scientific director.

    The projects were selected after a rigorous process that saw a committee of international experts visit six short-listed labs before making a final decision on the award recipients.

    Familiar faces, innovative approaches

    All three research teams have a proven track-record in cancer research and have received funding from the TFRI before.  With this new funding, the teams hope to continue building on previous discoveries with the hopes of beginning to transition their ground-breaking research out of the lab and into clinics.

    “The only way you can do this type of research is through a team grant,” says Dr. David Huntsman (UBC, BC Cancer), lead investigator for the renewed forme fruste program. “The New Frontiers Grant is Canada’s premiere grant for team science cancer research and has allowed us to take on a large challenge – something much greater than any of us would be able to tackle as individuals – and be able to deliver discoveries that would otherwise be impossible to find.”

    Learn more about the research of the 2018 Terry Fox New Frontiers Program Project Grant winners:

    About The Terry Fox Research Institute (TFRI) 

    Launched in October 2007, The Terry Fox Research Institute is the brainchild of The Terry Fox Foundation and today functions as its research arm. TFRI seeks to improve significantly the outcomes of cancer research for the patient through a highly collaborative, team-oriented, milestone-based approach to research that will enable discoveries to translate quickly into practical solutions for cancer patients worldwide. TFRI collaborates with over 70 cancer hospitals and research organizations across Canada. TFRI headquarters are in Vancouver, BC. www.tfri.ca 

    For more information, contact:
    Peter Mothe
    Communications Specialist
    604-675-8000 ext.7630
    C: 604-773-2827

Back to Top